An attractive approach to combat disease is to target theregulation of cell function. At the heart of this task are nuclear receptors (NRs); which control functions such as gene transcription. Arguably, the key player in this regulatory machinery is the retinoid X receptor (RXR). This NR associates with a third of the NRs found in humans. Scientists have hypothesized that controlling the activity of RXR is an attractive approach to control cellular functions that modulate diseases such as cancer, diabetes, Alzheimer's disease and Parkinson's disease. In this review, we will describe the key features of the RXR, present a historic perspective of the first RXR agonists, and discuss various templates that have been reported to activate RXR with a focus on their molecular structure, biological activity, and limitations. Finally, we will present an outlook of the field and future directions and considerations to synthesize or modulate RXR agonists to make these compounds a clinical reality.
An attractive apn class="Gene">proach to combat disease is to target theregulation of cell function. At the heart of this task are nuclear receptors (NRs); which control functions such as gene transcription. Arguably, the key player in this regulatory machinery is the retinoid X receptor (RXR). This NR associates with a third of the NRs found in humans. Scientists have hypothesized that controlling the activity of RXR is an attractive approach to control cellular functions that modulate diseases such as cancer, diabetes, Alzheimer's disease and Parkinson's disease. In this review, we will describe the key features of the RXR, present a historic perspective of the first RXR agonists, and discuss various templates that have been reported to activate RXR with a focus on their molecular structure, biological activity, and limitations. Finally, we will present an outlook of the field and future directions and considerations to synthesize or modulate RXR agonists to make these compounds a clinical reality.
Authors: T Yamauchi; H Waki; J Kamon; K Murakami; K Motojima; K Komeda; H Miki; N Kubota; Y Terauchi; A Tsuchida; N Tsuboyama-Kasaoka; N Yamauchi; T Ide; W Hori; S Kato; M Fukayama; Y Akanuma; O Ezaki; A Itai; R Nagai; S Kimura; K Tobe; H Kagechika; K Shudo; T Kadowaki Journal: J Clin Invest Date: 2001-10 Impact factor: 14.808
Authors: Lyndsey A Reich; Jessica A Moerland; Ana S Leal; Di Zhang; Sarah Carapellucci; Beth Lockwood; Peter W Jurutka; Pamela A Marshall; Carl E Wagner; Karen T Liby Journal: Sci Rep Date: 2022-01-07 Impact factor: 4.379